Zoetis (ZTS) Stock Forecast & Price Target

Zoetis has significantly expanded its direct engagement with pet owners, as evidenced by the enrollment of 2.5 million pet owners in the Zoetis Petcare Rewards program, a substantial increase from 708,000 in 2018, alongside an investment of over $120 million in 2023 for marketing efforts in the U.S. The company’s revenue from Simparica has notably contributed to growth, generating $356 million in Q3 with a year-over-year increase of 7%. Furthermore, key dermatological products such as Apoquel, Apoquel chewable, and Cytopoint have shown resilient performance, achieving $469 million in global revenue with a growth of 3% year-over-year in Q3.

Zoetis has lowered its 2025 revenue guidance to a range of $9.400 billion to $9.475 billion, indicating a decline in organic operational growth expectations compared to previous forecasts, which could signal weakening demand in its key markets. The company's performance in the OA pain segment has sharply declined by 11% year-over-year, attributed to concerns surrounding the safety profile of its product Librela, which has negatively impacted overall sales. Furthermore, the U.S. companion animal health segment, crucial for Zoetis's revenue, reported flat growth, exacerbated by increased competition and a decline in veterinary clinic visits, hinting at potential challenges ahead for the company's core business.